These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26031770)

  • 21. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.
    Teng YT; Su WJ; Hou JW; Huang SF
    Chang Gung Med J; 2004 May; 27(5):379-84. PubMed ID: 15366815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
    Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
    J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.
    Bali DS; Tolun AA; Goldstein JL; Dai J; Kishnani PS
    Muscle Nerve; 2011 May; 43(5):665-70. PubMed ID: 21484825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.
    Rucker M; Fraites TJ; Porvasnik SL; Lewis MA; Zolotukhin I; Cloutier DA; Byrne BJ
    Development; 2004 Jun; 131(12):3007-19. PubMed ID: 15169761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
    Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
    Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pain in adult patients with Pompe disease: a cross-sectional survey.
    Güngör D; Schober AK; Kruijshaar ME; Plug I; Karabul N; Deschauer M; van Doorn PA; van der Ploeg AT; Schoser B; Hanisch F
    Mol Genet Metab; 2013 Aug; 109(4):371-6. PubMed ID: 23849261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for late-onset Pompe disease in western Denmark.
    Hansen JS; Pedersen EG; Gaist D; Bach FW; Vilholm OJ; Sandal B; Weitemeyer L; Nielsen K; Schlesinger FE; Preisler N; Vissing J; Andersen H
    Acta Neurol Scand; 2018 Jan; 137(1):85-90. PubMed ID: 28832912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme therapy for Pompe disease: from science to industrial enterprise.
    Reuser AJ; Van Den Hout H; Bijvoet AG; Kroos MA; Verbeet MP; Van Der Ploeg AT
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S106-11. PubMed ID: 12373583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature.
    Hobson-Webb LD; Proia AD; Thurberg BL; Banugaria S; Prater SN; Kishnani PS
    Mol Genet Metab; 2012 Aug; 106(4):462-9. PubMed ID: 22664150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.
    Laforêt P; Laloui K; Granger B; Hamroun D; Taouagh N; Hogrel JY; Orlikowski D; Bouhour F; Lacour A; Salort-Campana E; Penisson-Besnier I; Sacconi S; Zagnoli F; Chapon F; Eymard B; Desnuelle C; Pouget J;
    Rev Neurol (Paris); 2013; 169(8-9):595-602. PubMed ID: 24008051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.
    Kyosen SO; Iizuka S; Kobayashi H; Kimura T; Fukuda T; Shen J; Shimada Y; Ida H; Eto Y; Ohashi T
    Gene Ther; 2010 Apr; 17(4):521-30. PubMed ID: 20033064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
    Ashe KM; Taylor KM; Chu Q; Meyers E; Ellis A; Jingozyan V; Klinger K; Finn PF; Cooper CG; Chuang WL; Marshall J; McPherson JM; Mattaliano RJ; Cheng SH; Scheule RK; Moreland RJ
    Mol Genet Metab; 2010 Aug; 100(4):309-15. PubMed ID: 20554235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for late-onset Pompe disease in Finland.
    Palmio J; Auranen M; Kiuru-Enari S; Löfberg M; Bodamer O; Udd B
    Neuromuscul Disord; 2014 Nov; 24(11):982-5. PubMed ID: 25047669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late form of Pompe disease with glycogen storage in peripheral nerves axons.
    Fidziańska A; Ługowska A; Tylki-Szymańska A
    J Neurol Sci; 2011 Feb; 301(1-2):59-62. PubMed ID: 21109266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.